Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

Phase 1

Withdrawn

Conditions: Acute Myeloid Leukemia

Interventions: Drug: G-CSF
Drug: Cytarabine
Drug: Fludarabine
Biological: Donor Natural Killer (NK) cells
Biological: ALT-801

First Posted Date: 2011-11-23

Last Posted Date: 2014-01-03

Lead Sponsor: Altor BioScience

Registration Number: NCT01478074

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Protocol in Acute Myeloid Leukemia With FLT3-ITD

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Midostaurin
Drug: Cytarabine
Drug: Daunorubicin

First Posted Date: 2011-11-22

Last Posted Date: 2020-06-04

Lead Sponsor: University of Ulm

Target Recruit Count: 451

Registration Number: NCT01477606

Locations: 🇦🇹
Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria
🇩🇪
Helios Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪
Städtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany

and more 52 locations

Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Recurrent Adult Hodgkin Lymphoma

Interventions: Biological: basiliximab
Drug: carmustine
Drug: etoposide
Drug: cytarabine
Drug: melphalan
Other: pharmacological study
Other: laboratory biomarker analysis
Procedure: autologous hematopoietic stem cell transplantation
Biological: yttrium Y 90-labeled basiliximab

First Posted Date: 2011-11-22

Last Posted Date: 2024-03-19

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 25

Registration Number: NCT01476839

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Advanced Myelodysplastic Syndrome

Interventions: Drug: Panobinostat
Drug: Cytarabine
Drug: Daunorubicin

First Posted Date: 2011-11-01

Last Posted Date: 2019-04-22

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 29

Registration Number: NCT01463046

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

Phase 2

Completed

Conditions: Lymphoblastic Lymphoma

Interventions: Drug: Prednisone
Drug: Vincristine
Drug: Daunorubicin
Drug: PEG-asparaginase
Drug: Erwinia asparaginase
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Thioguanine
Drug: Clofarabine
Drug: Methotrexate
Drug: Mercaptopurine
Drug: Dexamethasone
Drug: Hydrocortisone
Drug: Etoposide

First Posted Date: 2011-10-13

Last Posted Date: 2022-06-28

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 23

Registration Number: NCT01451515

Locations: 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)

Phase 2

Completed

Conditions: Leukemia
Myeloproliferative Diseases

Interventions: Drug: Clofarabine
Drug: Cytarabine

First Posted Date: 2011-10-03

Last Posted Date: 2018-07-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 81

Registration Number: NCT01444742

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia

Phase 1

Completed

Conditions: Acute Myeloblastic Leukemia

First Posted Date: 2011-09-16

Last Posted Date: 2017-04-25

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 55

Registration Number: NCT01435343

Locations: 🇪🇸
Hospital Clínic de Barcelona, Barcelona, Spain
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸
Hospital Duran i Reynals - ICO L'Hospitalet, Barcelona, Spain

and more 7 locations

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Phase 2

Active, not recruiting

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Acute Lymphoblastic Leukemia
Adult Acute Lymphoblastic Leukemia in Complete Remission
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Philadelphia Chromosome Positive
Untreated Adult Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Drug: Ponatinib
Drug: Ponatinib Hydrochloride
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine
Drug: Vincristine Sulfate

First Posted Date: 2011-08-29

Last Posted Date: 2024-05-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 88

Registration Number: NCT01424982

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML<60a

Phase 3

Conditions: Acute Myeloid Leukaemia

Interventions: Drug: Cytarabine

First Posted Date: 2011-08-11

Last Posted Date: 2011-08-11

Lead Sponsor: University of Leipzig

Target Recruit Count: 850

Registration Number: NCT01414231

Locations: 🇩🇪
University of Leipzig, Hematology, Leipzig, Germany

S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: bendamustine hydrochloride
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: leucovorin calcium
Drug: methotrexate
Drug: vincristine sulfate

First Posted Date: 2011-08-09

Last Posted Date: 2021-10-29

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 53

Registration Number: NCT01412879

Locations: 🇺🇸
Illinois CancerCare - Galesburg, Galesburg, Illinois, United States
🇺🇸
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States
🇺🇸
Wenatchee Valley Medical Center, Wenatchee, Washington, United States

and more 200 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy